Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Azurrx Biopharma Inc (AZRX)

Azurrx Biopharma Inc (AZRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,175
  • Shares Outstanding, K 9,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,670 K
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.31
Trade AZRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.80
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/20/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +82.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.36 +2.68%
on 09/20/21
7.05 -51.06%
on 09/10/21
-2.36 (-40.60%)
since 08/20/21
3-Month
3.36 +2.68%
on 09/20/21
8.57 -59.74%
on 08/18/21
-4.58 (-57.06%)
since 06/21/21
52-Week
3.36 +2.68%
on 09/20/21
26.30 -86.88%
on 01/22/21
-4.15 (-54.62%)
since 09/21/20

Most Recent Stories

More News
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22

AZRX : 3.45 (+2.07%)
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420

AZRX : 3.45 (+2.07%)
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

BOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma , Inc. (“AzurRx” or the “Company”) ( NASDAQ: AZRX ), a company specializing in the development of targeted, non-systemic therapies...

AZRX : 3.45 (+2.07%)
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies...

AZRX : 3.45 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Azurrx Biopharma, Inc. is a biopharmaceutical company. It focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company's product pipeline consists of MS1819, a recombinant lipase for the treatment of exocrine pancreatic...

See More

Key Turning Points

3rd Resistance Point 3.89
2nd Resistance Point 3.78
1st Resistance Point 3.61
Last Price 3.45
1st Support Level 3.33
2nd Support Level 3.22
3rd Support Level 3.05

See More

52-Week High 26.30
Fibonacci 61.8% 17.54
Fibonacci 50% 14.83
Fibonacci 38.2% 12.12
Last Price 3.45
52-Week Low 3.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar